Search | IOVS | ARVO Journals

View

Showing 1 – 11 of 11

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

A Phase 1b Multi-Center, Open Label, Single-Arm Safety Study of Intravitreal Pegcetacoplan Supporting the Phase 3 DERBY and OAKS Studies for Geographic Atrophy: A Solution to “Tarmac Delay"

Nathan Steinle; jeffrey heier; Rishi P Singh; David S Boyer; Eleonora M Lad; Ravi Metlapally; Ramiro Ribiero; Charles Clifton Wykoff; Chris Holmes

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):278. doi:

ARVO Annual Meeting Abstract July 2019

Evaluation of Baseline Factors on Progression in a Large Phase-2 Clinical Trial for Geographic Atrophy (FILLY Study)

Nathan Steinle; Mohamed Hamdani

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):973. doi:

ARVO Annual Meeting Abstract July 2018

Outcomes Based on Baseline (BL) Features of Choroidal Neovascularization (CNV) in Patients (pts) with Neovascular Age-related Macular Degeneration (nAMD): Post-hoc Analysis from the VIEW Studies

Nathan Steinle; Diana V Do; Desmond Thompson; Andrea Gibson; Namrata Saroj

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1619. doi:

ARVO Annual Meeting Abstract July 2018

Treat and Extend Versus Bi-monthly dosing with Aflibercept for the Treatment of Diabetic Macular Edema, One Year Outcomes (EVADE Study)

Jack M Giust; Alessandro Castellarin; Nathan Steinle; Dante Joseph Pieramici; Robert F. See; Robert L Avery; Gabriel M Gordon; Dilsher Dhoot

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1957. doi:

ARVO Annual Meeting Abstract June 2017

Ranibizumab versus verteporfin photodynamic therapy for myopic choroidal neovascularization: Results from RADIANCE

Nathan Steinle; Avanti Ghanekar; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5920. doi:

ARVO Annual Meeting Abstract September 2016

Comparison of Three Non-surgical Treatments for Vitreomacular Traction (VMT)

Nathan Steinle; Dilsher Dhoot; Dante Joseph Pieramici; Robert F See; Alessandro Castellarin; Steven Couvillion; Maan Nasir; Robert L Avery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Retrospective Review of Snellen Visual Acuity in Patients with Diabetic Macular Edema, Prior to Initiation of Anti-VEGF Treatment

Sarah Fishbein; Nathan Steinle; Gina Hong

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2094. doi:

ARVO Annual Meeting Abstract June 2015

Intravitreal Perfluoropropane Gas (C3F8) Versus Ocriplasmin for Vitreomacular Traction (VMT)

Nathan Steinle; Dilsher Dhoot; Carlos Quezada; Ma'an A Nasir; Dante Joseph Pieramici; Robert See; Steve Couvillion; Alessandro Castellarin; Robert L Avery

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3515. doi:

ARVO Annual Meeting Abstract April 2014

Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients with DME

Robert L Avery; Alessandro Castellarin; Nathan Steinle; Dilsher Dhoot; Dante Joseph Pieramici; Robert F See; Stephen Couvillion; Ma Nasir; Kha Le; Jennifer Visich

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):586. doi:

ARVO Annual Meeting Abstract April 2014

Outer Band Reflectivity Changes on SD-OCT Following Intravitreal Ocriplasmin for Vitreomacular Traction (VMT) and macular holes (MH)

Nathan C Steinle; Carlos Quezada; Ma Nasir; Dante Joseph Pieramici; Alessandro Castellarin; Robert F See; Stephen Couvillion; Dilsher Dhoot; Melvin Rabena; Robert L Avery; California Retina Consultants

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):296. doi:

ARVO Annual Meeting Abstract March 2012

0.5 Mg Versus 2.0 Mg Ranibizumab For Macular Edema Due To CRVO

Melvin Rabena; Dante Pieramici; Ma'an Nasir; Alessandro Castellarin; Robert See; Stephen Couvillion; Nathan Steinle; Robert Avery

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):952. doi:

Advertisement